Infanrix Polio (Pertussis Toxoid Adsorbed On Aluminium Hydroxide, Pertussis Pertactin Adsorbed On Aluminium Hydroxid)

The vaccine contains inactivated diphtheria and tetanus toxoids, pertussis antigens (toxoid and pertactin) bound to aluminium hydroxide, and inactivated poliovirus. These components stimulate the immune system to produce specific antibodies and memory cells that neutralise the toxins and block poliovirus infection.

The dose and schedule are determined by the prescribing healthcare professional based on national immunisation guidelines. Typically, the vaccine is given as a series of intramuscular injections at specific ages, but the exact regimen must be set by the clinician.

Infanrix Polio is not recommended for use in pregnant women because safety data are limited. Women who are breastfeeding should consult their healthcare provider, as the vaccine is generally intended for infants rather than for maternal administration.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Infanrix Polio is a licensed, EU‑approved combination vaccine that includes aluminium‑hydroxide‑adsorbed pertussis antigens, offering comparable immunogenicity to other DTP‑Polio products such as Daptacel or Pentacel. Differences may lie in specific antigen formulations, adjuvant content and regulatory approvals, but all aim to provide protection against the same four diseases.

The vaccine must be stored at 2‑8 °C, protected from light, and kept in its original packaging. It should never be frozen or shaken. If temperature excursions occur, discard the product according to the manufacturer’s guidance.

Infanrix Polio is given by intramuscular injection, usually into the anterolateral thigh of infants or the deltoid muscle of older children, following the recommended immunisation schedule. Administration should be performed by a qualified healthcare professional.

The most serious adverse events include severe allergic reactions (anaphylaxis), seizures, high‑grade fever, and rare neurologic complications such as encephalopathy. Any signs of a serious reaction require immediate medical attention.

Infanrix Polio is contraindicated in individuals with a known severe allergy to any vaccine component, including aluminium salts, or in those who have experienced a previous severe reaction to a DTP‑Polio vaccine. Children with severe immunodeficiency should receive the vaccine only after specialist evaluation.